KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2025)

GoodRx Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $261.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 41.6% year-over-year to $261.8 million; the TTM value through Dec 2025 reached $261.8 million, down 41.6%, while the annual FY2025 figure was $261.8 million, 41.6% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $261.8 million at GoodRx Holdings, down from $273.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $990.5 million in Q1 2021 and bottomed at $261.8 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $729.7 million (2022), against an average of $641.9 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 933.49% in 2021 before it crashed 46.69% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $941.1 million in 2021, then fell by 19.55% to $757.2 million in 2022, then decreased by 11.21% to $672.3 million in 2023, then tumbled by 33.31% to $448.3 million in 2024, then plummeted by 41.6% to $261.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Cash & Equivalents are $261.8 million (Q4 2025), $273.5 million (Q3 2025), and $281.3 million (Q2 2025).